All News
Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didn’t affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Phenotypes of GCA:
Pt dx by PET compared to TA biopsy were:
- younger
-longer disease before dx
-more frequent extremity claudication (still overall low)
-less cranial / TA sx
@RheumNow #ACR25 Abstract 0759 https://t.co/ilwa3eYmRq
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Cool study using vasculitis patient-powered reserach network (VPPRN)
"SNOT-22" tool captures sinonasal symptoms; associated with disease activity (expected) but also worse among pts even in remission
Very important impacter of QOL in AAV
#ACR25 @RheumNow Abstr0725 https://t.co/NQBW8VnYFS
Links:
Mike Putman EBRheum ( View Tweet)
No seasonal pattern in GCA!
We have also looked at this in our data and similarly found no trends
It sure feels like GCA comes in waves, but data does not bear this out
#ACR25 @RheumNow Abstr#0754 https://t.co/4y2elYmCRT
Mike Putman EBRheum ( View Tweet)
Accdg to this retro analysis of their prospective cohort study from Toronto, 47 pts (10%) had D2M axSpA of whom 14 had tx-refractory dse.
D2M pts - longer symptom duration; ⬆️ASDAS, BASDAI, BASMI, BASFI & ⬆️CRP
💡Consider non-dse factors in D2M pts
#ACR25 @RheumNow Abs0547 https://t.co/MUUyyELbw8
sheila RHEUMarampa ( View Tweet)
Real-world T2T strategy from MONITOR-PsA cohort:
🎯 At 48 weeks - 33.6% (49/146) of pts achieved PASDAS 'moderate' response & 37% (54/146) achieved a 'good' response
This was close to the T2T outcomes of the TICOPA trial
Adapt a T2T approach in PsA tx
#ACR25 @RheumNow Abs0572 https://t.co/FPiFIiO8Oe
Links:
sheila RHEUMarampa ( View Tweet)
RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a
Richard Conway RichardPAConway ( View Tweet)
Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective
@RheumNow #ACR25 https://t.co/TJ4d56oBaJ
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
SLE & arthritis: Is there a difference?
Abstract #0629:
- Non-deforming (ND): 73% | Jaccoud’s: 19% | Rhupus: 8%
- Vs ND, Rhupus had lower odds of type I IFN signature
- Time to deformities: Jaccoud's ~2 yrs vs Rhupus ~5 yrs
- RNP+ predictive of Jaccoud’s
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Managing lupus is complex. How do we ensure quality care?
Abstract #0218 convened 8 focus groups:
✅ Support for patient navigators
⚠️ Barriers: low resources, staff turnover
💻 Solution: EHR outreach workflow to flag missed visits & labs
@RheumNow #ACR25 https://t.co/BWaIMMEPit
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
DESIR cohort of early axSpA:
✳️Factors assoc w/ D2M axSpA - female sex, ⬆️ASDAS-CRP ⬆️BASFI ⬆️ASQOL at baseline.
✳️ Low prevalence of pts meeting D2M definition (15 pts - 8.4% bDMARD-treated)
#ACR25 @RheumNow Abs0544 https://t.co/fBUh3myKcz
sheila RHEUMarampa ( View Tweet)
Abstract #0189: Rheumatologists are early adopters and high utilizers of #AI scribes.
📊 Adoption: 41%
🧑💻 Retention: 100%
💬 High utilizers (> 70% visits): 83%. The highest among IM subspecialties
🕒 AI scribes reduced EHR time across all measures.
@RheumNow #ACR25 https://t.co/TBurWUKhMl
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
In a nationally representative NHANES sample, inflammatory back pain (IBP) was not associated with HLA-B27 positivity or elevated CRP, regardless of IBP criteria used (e.g., Berlin 8a: OR 0.88, p=0.876). IBP alone may be insufficient for identifying axSpA-related immunogenetic or https://t.co/82NjVU171z
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Getting down with Jack at the @RheumNow #ACR25 stand - come and say hello!
(and Ask Cush Anything - scan the QR code, and maybe end up on the podcast!) https://t.co/0u0boHIIR3
David Liew drdavidliew ( View Tweet)
Come to our first #HealthLiteracy poster of #ACR25!
#0190
Cluster analysis >900 people with IA
Lowest health literacy cluster assoc w:
4× ⬆️anxiety/depression
2× ⬆️disease activity, vs highest HL
Higher HL assoc w older age & ⬆️comorbidities but fewer mental health Sx
@RheumNow https://t.co/iIRXaOl4qZ
Links:
Mrinalini Dey DrMiniDey ( View Tweet)
#0773 Anti-MDA5 epitope mapping identifies key regions (aa 201-300, 601-700) linked to treatment resistance & poor prognosis in DM-ILD and even IIPs.
Epitope-specific antibodies could refine risk stratification & guide therapy in ILD beyond autoimmune disease. @RheumNow #ACR25 https://t.co/moRffVGZPn
Mrinalini Dey DrMiniDey ( View Tweet)
#LLM can be #virtual #tutor for
👇
#OSCE
RCT - better competence &confidence
#AI & #medical #education
AI trained to #tutor
Also grading OSCE #AI + human
@RheumNow @ACRheum #26S17 https://t.co/CzKoxyjpY8
Janet Pope Janetbirdope ( View Tweet)
#Pros and #cons of #AI
Need to know both
Need to assess AI #quality and #accuracy
‘Assume AI WILL be used’
JHausmann
By trainees, patients and medical personnel
Train #faculty re #AI
#ACR25 @RheumNow @ACRheum
#26S17 https://t.co/CvPDQPbueW
Janet Pope Janetbirdope ( View Tweet)
Topical therapies in cutaneous lupus - find the right level
Victoria Werth #ACR25 SLE guideline session @RheumNow https://t.co/o3gBuFkr4n
Links:
David Liew drdavidliew ( View Tweet)
